HENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity

Stock News01-12 22:50

HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National Medical Products Administration, with clinical trials to be conducted in the near future. According to the Drug Administration Law of the People's Republic of China and relevant regulations, following a review, the HRS-7535 tablets, accepted on October 27, 2025, were deemed to meet the requirements for drug registration, approving the product to proceed with clinical trials. The applied indication is for the treatment of hypertension complicated by overweight or obesity. Reportedly, HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. It is intended for treating type 2 diabetes (T2DM) and weight loss through mechanisms such as activating human GLP-1R to promote pancreatic insulin secretion, reduce glucagon secretion, inhibit gastric emptying, as well as influencing the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake. Globally, no oral small-molecule GLP-1R agonists are currently on the market. As of now, the cumulative R&D investment for projects related to HRS-7535 tablets amounts to approximately 369.4 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140159645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140159645","market":"sh","top_or_hot":-1,"title":"HENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National Medical Products Administration, with clinical trials to be conducted in the near future.\nAccording to the Drug Administration Law of the People's Republic of China and relevant regulations, following a review, the HRS-7535 tablets, accepted on October 27, 2025, were deemed to meet the requirements for drug registration, approving the product to proceed with clinical trials.\nThe applied indication is for the treatment of hypertension complicated by overweight or obesity.\nReportedly, HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist.\nIt is intended for treating type 2 diabetes (T2DM) and weight loss through mechanisms such as activating human GLP-1R to promote pancreatic insulin secretion, reduce glucagon secretion, inhibit gastric emptying, as well as influencing the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake.\nGlobally, no oral small-molecule GLP-1R agonists are currently on the market.\nAs of now, the cumulative R&D investment for projects related to HRS-7535 tablets amounts to approximately 369.4 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National Medical Products Administration, with clinical trials to be conducted in the near future.\nAccording to the Drug Administration Law of the People's Republic of China and relevant regulations, following a review, the HRS-7535 tablets, accepted on October 27, 2025, were deemed to meet the requirements for drug registration, approving the product to proceed with clinical trials.\nThe applied indication is for the treatment of hypertension complicated by overweight or obesity.\nReportedly, HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist.\nIt is intended for treating type 2 diabetes (T2DM) and weight loss through mechanisms such as activating human GLP-1R to promote pancreatic insulin secretion, reduce glucagon secretion, inhibit gastric emptying, as well as influencing the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake.\nGlobally, no oral small-molecule GLP-1R agonists are currently on the market.\nAs of now, the cumulative R&D investment for projects related to HRS-7535 tablets amounts to approximately 369.4 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997245177.USD","symbol_name":"安联神洲A股基金","start_time":0,"source_url":"","article_id":"1140159645","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140159645","pubTimestamp":1768229452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK0239":"医药制造","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0183":"MSCI概念","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0188":"融资融券","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0012":"证金概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0028":"国家队","LU0359201612.USD":"贝莱德中国基金A2","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK1191":"制药","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0060":"抗癌","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0196":"行业龙头","01276":"恒瑞医药","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD"},"translate_title":"恒瑞医药(01276)：HRS-7535片获批临床试验靶向高血压伴跑赢大盘或肥胖","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National Medical Products Administration, with clinical trials to be conducted in the near future.\nAccording to the Drug Administration Law of the People's Republic of China and relevant regulations, following a review, the HRS-7535 tablets, accepted on October 27, 2025, were deemed to meet the requirements for drug registration, approving the product to proceed with clinical trials.\nThe applied indication is for the treatment of hypertension complicated by overweight or obesity.\nReportedly, HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist.\nIt is intended for treating type 2 diabetes (T2DM) and weight loss through mechanisms such as activating human GLP-1R to promote pancreatic insulin secretion, reduce glucagon secretion, inhibit gastric emptying, as well as influencing the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake.\nGlobally, no oral small-molecule GLP-1R agonists are currently on the market.\nAs of now, the cumulative R&D investment for projects related to HRS-7535 tablets amounts to approximately 369.4 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140159645","isCrawlerRequest":true}